Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
- First preliminary efficacy data from the clinical trial with HDP-101 in multiple myeloma published
- Presentation of preclinical and clinical data of the proprietary ADC technology platforms at the AACR Meeting 2024
- HDP-101 granted Orphan Drug Designation by the FDA
- Sale of a portion of future royalties for TLX250-CDx to HealthCare Royalty
- Professor Andreas Pahl takes over as Chief Executive Officer
Ladenburg, Germany, 11 July 2024 – Heidelberg Pharma AG (FSE: HPHA) published today its financial report on the first six months of 2024 (1 December 2023 – 31 May 2024).
Professor Andreas Pahl, CEO of Heidelberg Pharma AG, commented: “We are very pleased with the positive preliminary efficacy data from the Phase I clinical trial with our ATAC development candidate HDP-101. In three patients from the fifth cohort, we saw an objective improvement in the disease (“partial remission”). One of these patients is currently showing further improvement in the development of the disease.
